STOCK TITAN
  1. Home
  2. Sec-filings
  3. TARS
  4. [Form 4] Tarsus Pharmaceuticals, Inc. Insider Trading Activity

Tarsus (TARS) director William J. Link granted options and RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tarsus Pharmaceuticals director William J. Link, PhD reported equity awards tied to his service as a non-employee director as of the company’s 2026 annual meeting of stockholders. He received grants of restricted stock units and stock options that provide future rights to Tarsus common shares.

The filing shows 3,837 stock options with an exercise price of $64.34 per share, vesting in full on the one-year anniversary of the grant date and expiring on June 24, 2036, subject to continued service. It also reports RSU awards covering 806 and 2,417 shares, with one grant vesting in full after one year and the other vesting in four equal installments from September 15, 2026 through June 15, 2027.

Positive

  • None.

Negative

  • None.
Insider LINK WILLIAM J PHD
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 3,837 $0.00 --
Grant/Award Restricted Stock Units 2,417 $0.00 --
Grant/Award Restricted Stock Units 806 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 3,837 shares (Direct, null); Restricted Stock Units — 2,417 shares (Direct, null)
Footnotes (1)
  1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.
Stock options granted 3,837 shares Annual non-employee director option grant at $64.34 exercise price
Option exercise price $64.34 per share Stock Option (right to buy) granted June 25, 2026
Option expiration June 24, 2036 Expiration date for 3,837-share stock option award
RSU grant 1 size 806 RSUs Vests in full on one-year anniversary of grant
RSU grant 2 size 2,417 RSUs Vests in four installments on 9/15/2026, 12/15/2026, 3/15/2027, 6/15/2027
Restricted Stock Unit financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option (right to buy) financial
"Stock Option (right to buy) with an exercise price of 64.3400 and expiration date of 2036-06-24."
non-employee director financial
"Granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders."
vesting financial
"The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LINK WILLIAM J PHD
(Last)(First)(Middle)
C/O TARSUS PHARMACEUTICALS, INC.
17700 LAGUNA CANYON ROAD, FLOOR 4
(Street)
IRVINE CALIFORNIA 92618
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$64.3406/25/2026A3,837 (1)06/24/2036Common Stock3,837$03,837D
Restricted Stock Units(2)06/25/2026A2,417 (3) (3)Common Stock2,417$02,417D
Restricted Stock Units(2)06/25/2026A806 (4) (4)Common Stock806$0806D
Explanation of Responses:
1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
3. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
4. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.
Remarks:
/s/ Scott Sieckert, Attorney-in-Fact06/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

Why did Tarsus (TARS) grant equity awards at the 2026 annual meeting?

The stock option and RSU grants were made in connection with William J. Link’s service as a non-employee director as of Tarsus’s 2026 annual meeting. Such annual equity grants are a common form of board compensation aligned with shareholder interests.